Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Vaxart, Inc.
  6. News
  7. Summary
    VXRT   US92243A2006

VAXART, INC.

(VXRT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Vaxart : Letter from OUM & Co. LLP (Form 8-K)

07/20/2021 | 06:04am EDT

July 19, 2021

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549-7561

Ladies and Gentlemen:

We have read Vaxart, Inc.'s statements included under Item 4.01 of its Form 8‑K dated July 19, 2021, and are in agreement with the statements contained therein concerning our firm in response to Item 304(a) of Regulation S-K.

Very truly yours,

/s/ OUM & Co. LLP

Disclaimer

Vaxart Inc. published this content on 20 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 July 2021 10:03:10 UTC.


ę Publicnow 2021
All news about VAXART, INC.
08:01aVAXART : #8239;to Present at the 2021 Cantor Virtual Global Healthcare Conferenc..
PR
09/16VAXART : Entry into a Material Definitive Agreement (form 8-K/A)
AQ
09/16VAXART, INC. : Entry into a Material Definitive Agreement, Termination of a Mate..
AQ
09/07VAXART : #8239;to Present at the H.C. Wainwright 23rd Annual Global Investment C..
PR
08/23VAXART : Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D...
PU
08/23VAXART, INC. : Change in Directors or Principal Officers, Financial Statements a..
AQ
08/23Vaxart, Inc. Appoints Julie M. Cherrington to the Board of Directors
CI
08/23VAXART : Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D...
PR
08/19Vaxart, Inc. Announces the Creation of an Eight-Member Scientific and Clinica..
CI
08/11INSIDER TRENDS : 90-Days of Insider Buying at Vaxart Interrupted with Share Disp..
MT
More news
Analyst Recommendations on VAXART, INC.
More recommendations
Financials (USD)
Sales 2021 1,76 M - -
Net income 2021 -77,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -12,4x
Yield 2021 -
Capitalization 1 054 M 1 054 M -
Capi. / Sales 2021 600x
Capi. / Sales 2022 57,1x
Nbr of Employees 28
Free-Float 99,4%
Chart VAXART, INC.
Duration : Period :
Vaxart, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VAXART, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 8,41 $
Average target price 12,50 $
Spread / Average Target 48,6%
EPS Revisions
Managers and Directors
Andrei Floroiu President CEO, CFO & Director
Todd C. Davis Chairman
Sean N. Tucker Chief Scientific Officer & Senior Vice President
Richard Schwartz Senior Vice President-Technical Operations
Shaily Jaini Garg SVP-Clinical Development & Project Management
Sector and Competitors
1st jan.Capi. (M$)
VAXART, INC.47.29%1 054
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
REGENERON PHARMACEUTICALS34.93%67 775
WUXI APPTEC CO., LTD.35.75%60 418
VERTEX PHARMACEUTICALS-20.33%48 850